ArticlePLoS genetics2025
Integrative transcriptomic analysis of Korean high-grade serous ovarian cancer.
Article in PLoS genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade serous ovarian cancer (HGSOC) is the predominant subtype of ovarian cancer and is characterized by a high rate of relapse after platinum-based chemotherapy. Herein, we present a comprehensive analysis of 111 Korean HGSOC samples using next-generation sequencing technology to elucidate their transcriptomic landscapes. Our investigation revealed the existence of four distinct transcriptional subtypes of ovarian cancer: immunoreactive, mesenchymal, proliferative, and differentiated, which is comparable to those of TCGA HGSOC transcriptional subgroups. Each subtype exhibited unique correlation networks and their immune cell composition was computationally determined. Notably, the immunoreactive cluster displayed the highest immune score, even in the context of pan solid-cancer types, accompanied by heightened expression of CD4+ and CD8+ T cells (P < 0.05), along with notable associations with neutrophil degranulation and antigen presentation pathways (FDR < 0.01). Conversely, the differentiated cluster demonstrated immunodepleted characteristics, featuring an elevated proportion of overexpressed cancer-germline antigens. We also identified several cancer-germline HGSOC antigens that could be further investigated as potential targets for immunological intervention in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.